Sanofi and partner AstraZeneca recently increased production capacity for their RSV antibody shot, sales of which jumped ...

The British pharma is making what it calls its largest U.S. manufacturing investment. Elsewhere, AbbVie expanded a ...

Septerna upped the size of its offering twice before pricing a stock sale that raised funds for its lead candidate, a ...

We’re investing in this future by working with Rancho on the next generation of our database. We’re creating a pathway to ...

The deal will give Lyell a dual-targeting CAR-T candidate for blood cancers. Relatedly, Lyell will also end development of ...

An agency panel recommended lowering the age for routine vaccination from 65 to 50, boosting the revenue outlook for multiple ...

Newly published data show the therapy reduced the rate of swelling attacks in people with hereditary angioedema, but didn't ...

As Sanofi prepares to halt U.S. marketing of its dengue vaccine in 2026, locally acquired infections in the country are ...

Xavier, who leads biotech venture investing for the big drugmaker, expects an uptick in IPOs as well as renewed interest in ...

While analysts still see value in Alto’s approach to brain drugmaking, investors may have lost some faith, as the biotech’s ...

Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will substantially expand the number of people ...

In a world first, a pig kidney preserved at subzero temperatures was successfully transported across the Atlantic Ocean ...